- Home
- SLRX vs CNSP Comparison
SLRX vs CNSP Comparison
Compare SLRX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- CNSP
- Stock Information
- Founded
- SLRX N/A
- CNSP 2017
- Country
- SLRX United States
- CNSP United States
- Employees
- SLRX N/A
- CNSP N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- SLRX Health Care
- CNSP Health Care
- Exchange
- SLRX Nasdaq
- CNSP Nasdaq
- Market Cap
- SLRX 3.6M
- CNSP 4.0M
- IPO Year
- SLRX N/A
- CNSP 2019
- Fundamental
- Price
- SLRX $4.18
- CNSP $9.54
- Analyst Decision
- SLRX
- CNSP Strong Buy
- Analyst Count
- SLRX 0
- CNSP 1
- Target Price
- SLRX N/A
- CNSP $20.00
- AVG Volume (30 Days)
- SLRX 316.4K
- CNSP 27.3K
- Earning Date
- SLRX 11-13-2025
- CNSP 11-14-2025
- Dividend Yield
- SLRX N/A
- CNSP N/A
- EPS Growth
- SLRX N/A
- CNSP N/A
- EPS
- SLRX N/A
- CNSP N/A
- Revenue
- SLRX N/A
- CNSP N/A
- Revenue This Year
- SLRX N/A
- CNSP N/A
- Revenue Next Year
- SLRX N/A
- CNSP N/A
- P/E Ratio
- SLRX N/A
- CNSP N/A
- Revenue Growth
- SLRX N/A
- CNSP N/A
- 52 Week Low
- SLRX $3.64
- CNSP $4.93
- 52 Week High
- SLRX $108.00
- CNSP $221.94
- Technical
- Relative Strength Index (RSI)
- SLRX 50.63
- CNSP 60.71
- Support Level
- SLRX $3.86
- CNSP $8.50
- Resistance Level
- SLRX $4.58
- CNSP $10.59
- Average True Range (ATR)
- SLRX 0.37
- CNSP 0.60
- MACD
- SLRX -0.14
- CNSP -0.06
- Stochastic Oscillator
- SLRX 45.45
- CNSP 56.22
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.